CSI, Imaging & Innovation 2017

on .

Friday June 30, 2017
Frankfurt, Germany
Main Room of the Congress Center

CSI, Imaging & Innovation 2017
Parallel Sessions
Seminar: Challenges with TAVI
Moderator: David Hildick-Smith, MD / Nalan Schnelle, MD

Agenda: 10:30-12:40

New standards for assessing neurologic damage in CV clinical trials - Andreas Baumbach, MD
Can we calculate the cost benefit ratio of embolic protection? - Andreas Baumbach, MD
Claret - tbd
Triguard (Keystone)
Azeem Latbib, MD
Emboline - tbd
Bicuspid and heavily calcified aortic valves: Experience with the Venus valve - tbd
Should we worry about transcatheter heart valve durability? - Danny Dvir
Valve in valve implantations: important lessons from bench to bedside - Danny Dvir
The valve has embolized - now what? - tbd
More than mild regulation after TAVI: assessment and management - Antonio Colombo, MD
Management of iliac rupture - Stefan Toggweiler

Keystone Heart Gains Worldwide Exposure!

on .

Keystone Heart’s interview appearance on Worldwide Business with kathy ireland® is set to air worldwide on 2 great stations! What an honor it was to be on this show and now to be rebroadcast for the world to take in.

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

on .

Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9% vs. 14.3%). Minor strokes were under detected without detailed NIHSS assessment.

The TriGuard Cerebral Protection Device is not commercially available in the USA.